Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Peking University People's Hospital

17 clinical trials · 17 recruiting · OTHER

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by Peking University People's Hospital

RECRUITINGNCT07291921

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics,...

This project aims to innovatively integrate multi-omics data, including plasma metabolomics, radiomics, and cfDNA multi-level information, combined with survival data (e.g., RFS),...

Sponsor: Peking University People's HospitalEnrolling: 1001 location
Lung NeoplasmsNeoadjuvant TherapyImmunotherapy+1
RECRUITINGPhase 1 / Phase 2NCT06880913

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

To evaluate the efficacy and safety of Nanobody-Based CD19/CD22 Tandem Dual Chimeric Antigen Receptor (CAR) T-cell therapy in patients with relapsed or refractory B-ALL

Sponsor: Peking University People's HospitalEnrolling: 501 location
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
RECRUITINGPhase 1NCT07143929

To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL

To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed PTCL.

Sponsor: Peking University People's HospitalEnrolling: 181 location
CD7 Positive R/R PTCL
RECRUITINGPhase 2NCT06418477

Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD

This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed monoclonal immunoglobulin deposition disease treated with daratumumab, bortezomib,...

Sponsor: Peking University People's HospitalEnrolling: 203 locations
Monoclonal Gammopathy of Renal Significance
RECRUITINGNCT07296627

Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients

To conduct a multicenter, prospective observational cohort study to investigate first-line immunotherapy patterns and clinical outcomes in NDMM patients in China. Leveraging the...

Sponsor: Peking University People's HospitalEnrolling: 5001 location
Newly Diagnosed Multiple Myeloma (NDMM)
RECRUITINGPhase 2 / Phase 3NCT06879379

KPD Consolidation After ASCT in NDMM Patients

This study aims to evaluate the efficacy and safety of post-transplant consolidation therapy with the KPD regimen (carfilzomib, pomalidomide, and dexamethasone) versus no...

Sponsor: Peking University People's HospitalEnrolling: 2023 locations
Multiple Myeloma, Newly Diagnosed
RECRUITINGNCT06697483

Risk Stratification and MRD-driven Maintenance for MM After ASCT

This study evaluates the maintenance strategy based on risk stratification and MRD status after stem cell transplantation. This is a single-arm, multicenter, prospective study....

Sponsor: Peking University People's HospitalEnrolling: 1004 locations
Multiple Myeloma
RECRUITINGNCT06727669

Longitudinal Cohort of Thrombosis and Hemostasis Diseases

This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients. This study will collect basic...

Sponsor: Peking University People's HospitalEnrolling: 30005 locations
Immune ThrombocytopeniaThrombotic Thrombocytopenic PurpuraHemophilia A, Acquired+13
RECRUITINGNCT07463937

A RWS of SC MTX in Chinese RA Patients

Design: A prospective, single-arm, multicenter, real-world study that does not interfere with the patient's treatment plan Primary Objective: 1\. To evaluate the effectiveness...

Sponsor: Peking University People's HospitalEnrolling: 100001 location
Rheumatoid Arthritis (RA)
RECRUITINGNCT07005479

Long-Term Outcomes in SLE at Peking University People's Hospital

This study aims to prospectively follow patients diagnosed with Systemic Lupus Erythematosus (SLE) at Peking University People's Hospital, assessing long-term outcomes such as...

Sponsor: Peking University People's HospitalEnrolling: 10001 location
Systemic Lupus Erythematosus
RECRUITINGNCT07162168

Automated Bone Age Estimation From Noncontrast Abdominal CT Using Deep Learning

This study is a retrospective analysis that uses abdominal CT scans, which were originally taken for other medical reasons, to estimate bone age. By applying advanced deep...

Sponsor: Peking University People's HospitalEnrolling: 30001 location
Bone AgingOsteoporosis Diagnosis
RECRUITINGNCT07474571

Evaluation of Musculoskeletal Aging and Related Disorders Via Advanced Clinical Imaging

Study Overview This clinical research focuses on the development and validation of a multimodal artificial intelligence (AI) platform designed for the automated diagnosis and...

Sponsor: Peking University People's HospitalEnrolling: 20001 location
OsteoarthitisOsteoporosis
RECRUITINGEarly Phase 1NCT07328711

Immunomodulatory Therapy and Predictors of Clinical Cure in Chronic Hepatitis B

Achieving clinical cure, defined as hepatitis B surface antigen (HBsAg) seroclearance, represents a major research focus and an ideal therapeutic goal for chronic hepatitis B...

Sponsor: Peking University People's HospitalEnrolling: 1321 location
Chronic Hepaititis B
RECRUITINGNCT06627309

Rapid dFLC Response Predict CHR in AL Amyloidosis

Light chain amyloidosis (AL amyloidosis) is a rare plasma cell dyscrasia characterized by the deposition of insoluble amyloid fibrils in multiple organ systems. The treatment of...

Sponsor: Peking University People's HospitalEnrolling: 508 locations
Systemic AL Amyloidosis
RECRUITINGNCT06699394

Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis

This study aims to evaluate the use of teclistamab in systemic AL amyloidosis and answer whether teclistamab can improve the rate of complete hematological response. This is a...

Sponsor: Peking University People's HospitalEnrolling: 202 locations
AL Amyloidosis
RECRUITINGNCT05563623

The Beijing Angle Closure Progression Study

The Beijing angle closure progression study (BAPS) aims to explore the 5-year incidence of PACS progressing to PAC or PACG and to determine the possible risk factors of disease...

Sponsor: Peking University People's HospitalEnrolling: 8251 location
Angle-Closure Glaucoma
RECRUITINGPhase 2NCT06794008

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.

Sponsor: Peking University People's HospitalEnrolling: 501 location
Systemic Lupus ErythematosusInflammatory MyopathySystemic Sclerosis (SSc)+6